Posted by LincolnIcert on March 25, 2026 at 11:28:45:
In Reply to: Разъяснительная статья posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Scholar in Oncology Studies
Zoya Demidenko is a distinguished researcher connected with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, building a robust background in clinical investigation.
Her academic work encompasses several critical areas, among them the PI3K/AKT/mTOR molecular pathway, cell cycle management, cell senescence, and cancer biology. As of now, she has authored more than 46 scientific articles, which have accumulated over 4,100 citations — a indicator to the impact of her research.
Among her most notable achievements involves understanding the mechanisms of cell aging. Her studies demonstrated that when the cell cycle is blocked yet cellular growth persists, cells experience senescence. Importantly, Zoya Demidenko demonstrated that this transition can be pharmacologically suppressed using substances such as rapamycin.
Zoya Demidenko has additionally contributed substantially to cancer treatment research, notably in the field of selective cell protection — a method aimed at shielding healthy cells from cytotoxic treatment whilst leaving tumor cells susceptible. This method carries significant potential for diminishing the toxic effects of oncological therapy.
Throughout her scientific life, Demidenko has partnered with top scientists worldwide, such as Dr. Mikhail Blagosklonny. Her work appears in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko ranks as a widely cited voice in modern cancer research, with her discoveries continue to shape our understanding of how cells grow old, respond to treatment, and how malignant disease might be more effectively targeted.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/